Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 37

1.

Insulin monotherapy compared with the addition of oral glucose-lowering agents to insulin for people with type 2 diabetes already on insulin therapy and inadequate glycaemic control.

Vos RC, van Avendonk MJ, Jansen H, Goudswaard AN, van den Donk M, Gorter K, Kerssen A, Rutten GE.

Cochrane Database Syst Rev. 2016 Sep 18;9:CD006992. [Epub ahead of print] Review.

PMID:
27640062
2.

A randomised trial of the effect and cost-effectiveness of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with screen-detected type 2 diabetes: the Anglo-Danish-Dutch Study of Intensive Treatment in People with Screen-Detected Diabetes in Primary Care (ADDITION-Europe) study.

Simmons RK, Borch-Johnsen K, Lauritzen T, Rutten GE, Sandbæk A, van den Donk M, Black JA, Tao L, Wilson EC, Davies MJ, Khunti K, Sharp SJ, Wareham NJ, Griffin SJ.

Health Technol Assess. 2016 Aug;20(64):1-86. doi: 10.3310/hta20640.

3.

Impact of UKPDS risk estimation added to a first subjective risk estimation on management of coronary disease risk in type 2 diabetes - An observational study.

Wind AE, Gorter KJ, van den Donk M, Rutten GE.

Prim Care Diabetes. 2016 Feb;10(1):27-35. doi: 10.1016/j.pcd.2015.04.006. Epub 2015 May 19.

PMID:
25997631
4.

New oral anticoagulants for nonvalvular atrial fibrillation in the elderly: Limited applicability in primary care.

Opstelten W, van den Donk M, Kuijpers T, Burgers J.

Eur J Gen Pract. 2015 Jun;21(2):145-9. doi: 10.3109/13814788.2014.989986. Epub 2014 Dec 12. Review.

PMID:
25495417
5.

New oral anticoagulants in patients with atrial fibrillation.

Opstelten W, van den Donk M, Kuijpers T, Burgers JS.

Lancet. 2014 Jul 5;384(9937):24. doi: 10.1016/S0140-6736(14)61104-1. No abstract available.

PMID:
24998808
6.

Effect of early multifactorial therapy compared with routine care on microvascular outcomes at 5 years in people with screen-detected diabetes: a randomized controlled trial: the ADDITION-Europe Study.

Sandbæk A, Griffin SJ, Sharp SJ, Simmons RK, Borch-Johnsen K, Rutten GE, van den Donk M, Wareham NJ, Lauritzen T, Davies MJ, Khunti K.

Diabetes Care. 2014 Jul;37(7):2015-23. doi: 10.2337/dc13-1544. Epub 2014 May 1.

PMID:
24784827
7.

[Important changes in the Dutch College of General Practitioners (NHG) practice guideline 'Atrial fibrillation': revised practice guideline issued].

van den Donk M, Opstelten W; Dutch College of General Practioners (NHG)..

Ned Tijdschr Geneeskd. 2013;157(38):A6697. Review. Dutch.

PMID:
24330799
8.
9.

Work stress, sense of coherence, and risk of type 2 diabetes in a prospective study of middle-aged Swedish men and women.

Eriksson AK, van den Donk M, Hilding A, Östenson CG.

Diabetes Care. 2013 Sep;36(9):2683-9. doi: 10.2337/dc12-1738. Epub 2013 May 1.

10.

[Summary of the NHG practice guideline 'Lower urinary tract symptoms in men'].

Blanker MH, Klomp MA, van den Donk M, van der Heide WK, Opstelten W, Burgers JS.

Ned Tijdschr Geneeskd. 2013;157(18):A6178. Review. Dutch.

PMID:
23635505
11.

Computerized decision support systems in primary care for type 2 diabetes patients only improve patients' outcomes when combined with feedback on performance and case management: a systematic review.

Cleveringa FG, Gorter KJ, van den Donk M, van Gijsel J, Rutten GE.

Diabetes Technol Ther. 2013 Feb;15(2):180-92. doi: 10.1089/dia.2012.0201. Review.

PMID:
23360424
12.

Remission of screen-detected metabolic syndrome and its determinants: an observational study.

den Engelsen C, Gorter KJ, Salomé PL, van den Donk M, Rutten GE.

BMC Public Health. 2012 Sep 13;12:778. doi: 10.1186/1471-2458-12-778.

13.

Advanced glycation end products measured by skin autofluorescence in a population with central obesity.

den Engelsen C, van den Donk M, Gorter KJ, Salomé PL, Rutten GE.

Dermatoendocrinol. 2012 Jan 1;4(1):33-8. doi: 10.4161/derm.17999.

14.

Does early intensive multifactorial treatment reduce total cardiovascular burden in individuals with screen-detected diabetes? Findings from the ADDITION-Europe cluster-randomized trial.

Simmons RK, Sharp SJ, Sandbæk A, Borch-Johnsen K, Davies MJ, Khunti K, Lauritzen T, Rutten GE, van den Donk M, Wareham NJ, Griffin SJ.

Diabet Med. 2012 Nov;29(11):e409-16. doi: 10.1111/j.1464-5491.2012.03759.x.

15.

High-sensitivity C-reactive protein to detect metabolic syndrome in a centrally obese population: a cross-sectional analysis.

den Engelsen C, Koekkoek PS, Gorter KJ, van den Donk M, Salomé PL, Rutten GE.

Cardiovasc Diabetol. 2012 Mar 14;11:25. doi: 10.1186/1475-2840-11-25.

16.

Intensive multifactorial treatment and cognitive functioning in screen-detected type 2 diabetes--the ADDITION-Netherlands study: a cluster-randomized trial.

Koekkoek PS, Ruis C, van den Donk M, Biessels GJ, Gorter KJ, Kappelle LJ, Rutten GE.

J Neurol Sci. 2012 Mar 15;314(1-2):71-7. doi: 10.1016/j.jns.2011.10.028. Epub 2011 Nov 16.

17.

Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial.

Griffin SJ, Borch-Johnsen K, Davies MJ, Khunti K, Rutten GE, Sandbæk A, Sharp SJ, Simmons RK, van den Donk M, Wareham NJ, Lauritzen T.

Lancet. 2011 Jul 9;378(9786):156-67. doi: 10.1016/S0140-6736(11)60698-3. Epub 2011 Jun 24. Erratum in: Lancet. 2012 Mar 3;379(9818):804.

18.

Screening for type 2 diabetes. Lessons from the ADDITION-Europe study.

van den Donk M, Sandbaek A, Borch-Johnsen K, Lauritzen T, Simmons RK, Wareham NJ, Griffin SJ, Davies MJ, Khunti K, Rutten GE.

Diabet Med. 2011 Nov;28(11):1416-24. doi: 10.1111/j.1464-5491.2011.03365.x.

PMID:
21679235
19.

Diabetes Care Protocol: effects on patient-important outcomes. A cluster randomized, non-inferiority trial in primary care.

Cleveringa FG, Minkman MH, Gorter KJ, van den Donk M, Rutten GE.

Diabet Med. 2010 Apr;27(4):442-50. doi: 10.1111/j.1464-5491.2010.02968.x.

PMID:
20536517

Supplemental Content

Loading ...
Support Center